[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 757
Citations 0
Observation
October 2016

Management of Antiplatelet Allergy After Cardiac Stenting

Author Affiliations
  • 1Department of Dermatology, Oregon Health and Science University, Portland, Oregon
JAMA Dermatol. 2016;152(10):1169-1170. doi:10.1001/jamadermatol.2016.1983

Clopidogrel is an antiplatelet agent used to prevent in-stent thrombosis after percutaneous coronary intervention (PCI). Discontinuation of clopidogrel therapy within 1 month of PCI results in in-stent thrombosis in more than 25% of patients and is associated with high mortality.1 Up to 6% of patients will develop a clopidogrel allergy but remain dependent on antiplatelet agents to prevent in-stent thrombosis.24 We report a case of generalized bullous fixed drug eruption associated with clopidogrel and review the recommended management strategies for clopidogrel allergy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×